ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Animal Model"

  • Abstract Number: 0078 • ACR Convergence 2024

    Inhibition of the Deubiquitinase TRABID in a Pre-clinical Mouse Model of Axial Spondyloarthritis Decreases Disease Severity

    Archita Srinath1, Daniele Mauro2, Mariia Korshko3, Shaghayegh Foroozan4, Mansi Aparnathi5, Francesco Ciccia6 and Nigil Haroon7, 1University of Toronto, Toronto, ON, Canada, 2University of Campania, Italy, Naples, Naples, Italy, 3University Health Network, Toronto, ON, Canada, 4University Health Network/University of Toronto, Toronto, ON, Canada, 5University Health Network, Toronto, Canada, 6University of Campania, Naples, Italy, 7Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Axial Spondyloarthritis is characterized by both inflammation and new bone formation. Current therapeutic targets aim to control inflammation, however, over 40% of patients do…
  • Abstract Number: 0939 • ACR Convergence 2024

    A Joint-targeting Peptide Enhances the Therapeutic Efficacy of Liposomal Drug Delivery in Experimental Rheumatoid Arthritis

    Hemalatha Nanjaiah, Rakeshchandra Meka, Bodhraj Acharya, Shivaprasad Venkatesha and Kamal Moudgil, University of Maryland School of Medicine, Baltimore, Baltimore, MD

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease of synovial joints, and it affects over 1 per cent of the population worldwide. Uncontrolled or…
  • Abstract Number: 2546 • ACR Convergence 2024

    Lipocalin-2 Drives Neuropsychiatric and Cutaneous SLE Through Regulation of Immune Cell Recruitment in Target Organs

    Sayra Garcia1, Elise Mike2, Jinghang Zhang2, Carla Cuda3 and Chaim Putterman4, 1Albert Einstein College of Medicine, New York, NY, 2Albert Einstein, Bronx, NY, 3Northwestern University, Chicago, IL, 4Albert Einstein College of Medicine, Safed, Israel

    Background/Purpose: About 20-40% of SLE patients develop neuropsychiatric SLE (NPSLE). NPSLE manifestations include impaired cognitive function and depression, both of which negatively impact the quality…
  • Abstract Number: 0087 • ACR Convergence 2024

    SYNCAR: An Engineered IL-2/IL-2R-system That Selectively Enhances CD19 CAR T Cells to Deplete B Cells and Provide Therapeutic Benefit in SLE and RA Mouse Models Without Lymphodepletion

    Ethan Jung1, Marie semana1, Ivan Cheng1, Helena Silva1, Sandro Vivona1, Somya Singh1, Michele Bauer1, Mohammed Ali1, Henry Rosas1, Woei Chang1, Deepti Rokkam1, Patrick Lupardus1, Martin Oft1 and Paul-Joseph Aspuria2, 1Synthekine, Menlo Park, 2Sythekine, Menlo Park, CA

    Background/Purpose: CD19 CAR-T therapy has demonstrated efficacy in autoimmune (AI) diseases like systemic lupus erythematosus (SLE) and lupus nephritis (LN), showing its potential beyond oncology.…
  • Abstract Number: 0950 • ACR Convergence 2024

    Immunization of Arthritis Prone Mice with Malondialdehyde-Acetaldehyde (MAA) Modified Vimentin Induces Fibrotic Lung Changes

    Wenxian Zhou1, Michael Duryee2, Nozima Aripova2, Jill Poole2, Carlos Hunter2, Amy Nelson2, Bryant England2, Ted Mikuls2 and Geoffrey Thiele2, 1University of Nebraska Medical Center, Bellevue, NE, 2University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Rheumatoid arthritis associated interstitial lung disease (RA-ILD) is the most overrepresented cause of death among RA patients, yet the mechanisms underlying lung fibrosis remain…
  • Abstract Number: 2597 • ACR Convergence 2024

    The Stromal-cell Derived Cytokine interleukin-17D Attenuates Joint Inflammation

    Jia (Sijia) Chen1, Roopa Madhu2, Catherine Manning3, Daniel Montoro4, Nataliya Yeremenko5, Kevin Wei6, ilya Korsunsky1, Dominique Baeten5 and Ellen Gravallese7, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Brookline, MA, 3Brigham and Women's Hospital, Dedham, MA, 4TenSixty Biosciences, Boston, MA, 5Amsterdam University Medical Centers, Amsterdam, Netherlands, 6Brigham and Women's Hospital at Harvard Medical School, Boston, MA, 7Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA

    Background/Purpose: The interleukin-17 (IL-17) family of cytokines consists of 6 evolutionarily conserved cytokines, IL-17A-F. Of these, IL-17A, B, C, and F play diverse roles in…
  • Abstract Number: 0088 • ACR Convergence 2024

    Profound B Cell Depletion and Repopulation with Predominantly Naïve B Cells in Non-Human Primates Achieved Through a Novel In Vivo CD8-Targeted Lipid Nanoparticle mRNA CAR

    Aric Frantz1, Romina Riener1, Annabel Wang1, Yanjie Bao1, Yan Zhang1, Daiki Matsuda1, John Li1, David Chu1, Theresa Hunter1, Qian Chen Yong1, Michelle Nguyen1, Stuart Sievers1, Duy Nguyen1, Scott Roberts1, Diana Galvan1, Jerel Boyd Vega1, Matthew Butcher1, Stanley Zhang1, Stephen Flynn1, Yi Kuo1, Steven Tanis1, John Scholler2, Gregor Adams1, Michael Rosenzweig1, Priya Karmali1, Adrian Bot1, Carl June2 and Haig Aghajanian1, 1Capstan Therapeutics, San Diego, CA, 2University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

    Background/Purpose: Ex vivo chimeric antigen receptor (CAR) T cell therapies have revolutionized cancer treatment and are demonstrating durable clinical efficacy in various autoimmune disease indications.…
  • Abstract Number: 0955 • ACR Convergence 2024

    Inhibition of Interleukin-2-Inducible T Cell Kinase with Soquelitinib Demonstrates Efficacy in Preventing Lung Damage in Murine Models of Systemic Sclerosis

    Goncalo Boleto1, Anne Cauvet2, James Rose3, Lih-Yun Hsu3, Richard A. Miller3 and Yannick Allanore4, 1Rheumatology Department, Unidade Local de Saúde Santa Maria, Centro Académico de Medicina de Lisboa, Lisboa, Portugal., Lisbon, Portugal, 2Université de Paris, Institut Cochin, INSERM U1016 CNRS UMR8104, Paris, France, 3Corvus Pharmaceuticals, 863 Mitten Road, Burlingame, Burlingame, CA, 4Université Paris Cité, Paris, France

    Background/Purpose: T cells abnormal activation plays a pivotal role in the early inflammatory stages of systemic sclerosis (SSc). Compelling evidence supports that SSc has a…
  • Abstract Number: 2603 • ACR Convergence 2024

    A Human Lupus Gut Pathobiont Accelerates Systemic Inflammation, Autoantibody Production and T Cell Dysregulation

    Gregg Silverman1 and Laurence Morel2, 1NYU Grossman School of Medicine, New York, NY, 2Joe R. & Teresa Lozano Long School of Medicine, San Antonio, TX

    Background/Purpose: The mechanisms by which the gut microbiome contributes to autoimmune pathogenesis remain poorly understood. In lupus patients, more than ten-fold blooms of Ruminococcus gnavus…
  • Abstract Number: 0090 • ACR Convergence 2024

    Parenchymal and Hematopoietic IFNγ Signaling Exhibits Dichotomous Effects in Murine Lupus

    Minjung Kim1, Anthony Marinov2, Haylee Cosgrove3, Xiaoyan Gong3, Mark Shlomchik3 and Jeremy Tilstra3, 1University of Illinois College of Medicine at Chicago, Chicago, IL, 2University of Pittsburgh, Homestead, PA, 3University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Lupus nephritis is the most common life-threatening end-organ complication of SLE, and response rates to current interventions remain poor. Notably, PD-L1 and other interferon-responsive…
  • Abstract Number: 0959 • ACR Convergence 2024

    Radiomics Non-Invasively Conveys Time-Resolved Molecular Pathway Activity in Experimental Fibrosing Interstitial Lung Disease

    David Lauer1, Matthias Brunner2, Hubert Gabrys3, Kerstin Klein2, Oliver Distler4, Britta Maurer5 and Janine Gote-Schniering2, 1University Hospital Bern, Bern, Switzerland, 2University of Bern, Bern, Switzerland, 3University Hospital Zurich, Zurich, Zurich, Switzerland, 4Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, 5University Hospital Bern, University Bern, Bern, Switzerland

    Background/Purpose: Interstitial lung disease (ILD) is a major cause of mortality in patients with autoimmune-related CTD such as SSc and RA. Molecular characterization of the…
  • Abstract Number: 2662 • ACR Convergence 2024

    In Vivo Generation of B Cell Depleting CAR T Cell Therapies for Treatment of Autoimmune Diseases

    Laurie Beitz1, Maura Parker1, Justin Ulrich-Lewis1, Kristen Mittelsteadt1, Rebecca Gottschalk1, Chris Nicolai1, Jim Qin1, Andrew Scharenberg1, Ryan Larson1, Byoung Ryu1, Eric Cavanaugh2, Weiliang Tang1, Seungjin Shin1, Kelsey Lynch1 and Hans-Peter Kiem2, 1Umoja Biopharma, Seattle, WA, 2Fred Hutch Cancer Research Center, Seattle, WA

    Background/Purpose: CAR T cell therapy promises to revolutionize the treatment of hematologic malignancies, and more recently has generated early data that it may afford long…
  • Abstract Number: 0094 • ACR Convergence 2024

    Small GTPase Rab4A Regulates Mouse Behavior Through Altered Serum Serotonin Levels and Microglial mTORC1 Activation in Lupus-prone B6.TC Mice

    Thomas Winans1, Xiaojing Wang2, Joshua Lewis2, Jessica Nolan1, Laurence Morel3 and Andras Perl4, 1SUNY Upstate Medical University, Syracuse, 2SUNY Upstate Medical University, Syracuse, NY, 3University of Texas health San Antonio, San Antonio, TX, 4SUNY, Syracuse, NY

    Background/Purpose: Rab4A is a small GTPase that is overexpressed in patients and mice with systemic lupus erythematosus (SLE, PubMed ID: 23897774; PubMed ID 31805010). Rab4A…
  • Abstract Number: 0964 • ACR Convergence 2024

    Engaging the PD-1 Pathway Attenuates Inflammation Associated Fibrosis in Systemic Sclerosis Fibroblasts and a Preclinical Mouse Model

    Maithri Aspari1, Voon Ong2, Klaus Soendergaard3, Esben Naeser4, Malene Hvid4, Angela Tam5, Shiwen Xu5, Christopher Denton6, David Abraham7, Bent Deleuran1 and Stinne Greisen8, 1Aarhus University, Aarhus, Denmark, 2University College London, London, England, United Kingdom, 3Aarhus University Hospital, Aarhus, Denmark, 4AARHUS UNIVERSITET, AARHUS C, Denmark, 5University College London, London, United Kingdom, 6University College London, Northwood, United Kingdom, 7UCL, London, United Kingdom, 8Aarhus University/Aarhus University Hospital, Aarhus, Denmark

    Background/Purpose: The precise molecular mechanisms driving fibrosis in diffuse cutaneous systemic sclerosis (dcSSc) remain to be elucidated. The immune regulatory programmed cell death protein 1…
  • Abstract Number: 0097 • ACR Convergence 2024

    The Human Lupus TREX1 D18N Mutation Engineered in C. Elegans Leads to Cell Death. What Can We Learn About Lupus Using C. Elegans?

    Htay Htay Kyi1, Patricia Barreto2, Yeshaswi Pulijala3, Thejasvi Venkatachalam3 and Martha Soto2, 1Rutgers New Jersey Medical School, Jersey City, NJ, 2Robert Wood Johnson Medical School, Piscataway, NJ, 3RWJ-PATHOLOGY-RESEARCH-PISC, Piscataway

    Background/Purpose: TREX1 gene encodes the three prime repair exonuclease 1 enzyme that degrades DNA. TREX1 plays a key role in genomic DNA degradation, cell death…
  • 1
  • 2
  • 3
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology